Compare Kimberly Clark Corp (KMB) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Smith & Nephew plc — how do they compare? Kimberly Clark Corp trades at $97.59 (market cap $32.51B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Kimberly Clark Corp is far larger — about 2.9× Smith & Nephew plc's market cap, and Kimberly Clark Corp pays the higher dividend (5.24%). Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 93 Days and Smith & Nephew plc for 121 Days on average.
| KMB | SNN | |
|---|---|---|
Market Cap | $32.51B | $11.10B |
Volume | 6,139,913 | 1,051,703 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $37.17 |
52-Week Low | $93.05 | $26.42 |
Typical Hold Time | 93 Days | 121 Days |
Enterprise Value | $38.07B | $14.13B |
Dividend Yield | 5.24% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $97.74, up 1.31% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong profitability with 11.79% net margins and 129.43% ROE, though Q2 2026 earnings missed expectations. Recent news highlights executive transitions and the pending Kenvue acquisition, while dividend sustainability questions emerge amid cash flow pressures. Analyst consensus remains cautious with 61% hold ratings despite a $117.25 price target suggesting 20% upside.
KMB presents a value opportunity with attractive dividend yield near 5%, but faces integration risks from the Kenvue deal and cash flow challenges. The stock's current discount to analyst targets offers potential upside if execution improves, though investors should monitor dividend coverage and acquisition integration closely given the bearish technical trend and mixed earnings performance.
Smith+Nephew (SNN) trades at $26.96, near its 52-week low, with bearish technical signals despite recent earnings beats. The company shows strong fundamentals with revenue growth to $6.16B in 2025 and improving profit margins of 10.08%. Recent product launches in trauma care and surgical robotics highlight innovation, but analyst sentiment remains cautious with 65% hold ratings.
Investment outlook is mixed: solid fundamentals and product pipeline offer upside, but technical weakness and analyst skepticism pose near-term risks. Key catalysts include execution on new product adoption and margin expansion, while risks involve competitive pressures and leadership transitions following the CFO's departure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
